Secura Bio Inc. acquires global rights to Farydak from Novartis
Secura Bio, Inc.,an integrated, commercial-stage biopharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies, announced that it has acquired the global rights to Farydak (panobinostat) from Novartis.
Farydak (panobinostat) is a prescription oral medication used in combination with proteasome inhibitors and corticosteroids to treat patients with relapsed or refractory multiple myeloma who had received prior treatments. Farydak is a member of the histone deacetylase (HDAC) inhibitor family with a very potent and unique mode of action slowing the growth of multiple myeloma cells.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins